Prolia
Biological
Amgen Inc.
Total Payments
$49.0M
Transactions
308,610
Doctors
60,768
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $600,946 | 696 | 527 |
| 2023 | $3.1M | 3,218 | 1,844 |
| 2022 | $4.0M | 3,098 | 1,881 |
| 2021 | $5.6M | 3,248 | 1,943 |
| 2020 | $7.2M | 6,267 | 3,776 |
| 2019 | $9.8M | 37,081 | 19,398 |
| 2018 | $10.3M | 105,101 | 35,032 |
| 2017 | $8.4M | 149,901 | 42,894 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $28.2M | 656 | 57.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12.0M | 7,245 | 24.4% |
| Food and Beverage | $5.9M | 293,034 | 12.1% |
| Travel and Lodging | $1.6M | 6,559 | 3.4% |
| Consulting Fee | $1.1M | 375 | 2.2% |
| Space rental or facility fees (teaching hospital only) | $130,097 | 114 | 0.3% |
| Education | $9,008 | 627 | 0.0% |
Payments by Type
Research
$28.2M
656 transactions
General
$20.8M
307,954 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Denosumab postlaunch safety database | Amgen Inc. | $11.1M | 0 |
| AMG 162_Denosumab 120 mg/mL High Concentration BE study | Amgen Inc. | $2.0M | 0 |
| Denosumab postlaunch safety database. | Amgen Inc. | $1.5M | 0 |
| Pediatric OI | Amgen Inc. | $1.2M | 2 |
| Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery | Amgen Inc. | $1.1M | 0 |
| Denosumab (DMAB) Switching in Glucocorticoid-induced osteoporosis (GIOP) | Amgen Inc. | $1.1M | 0 |
| Pediatric OI. | Amgen Inc. | $1.1M | 0 |
| Effects of Denosumab in Women with Anorexia Nervosa | Amgen Inc. | $1.0M | 0 |
| Comparative antiresorptive efficacy of alendronate or raloxifene following | Amgen Inc. | $871,110 | 0 |
| The effects of 12-months of denosumab on bone density, quality and strength in prevalent kidney transplant recipients | Amgen Inc. | $632,268 | 0 |
| PROUD: Preventing Osteoporosis Using Denosumab | Amgen Inc. | $564,555 | 0 |
| Race and Bone Health and Cardiometabolic Consequences of Androgen Deprivation Therapy For Prostate Cancer | Amgen Inc. | $492,678 | 0 |
| A Phase II, single arm clinical study of denosumab effect on breast density and breast tissue biomarkers | Amgen Inc. | $450,947 | 0 |
| Bisphosphonates for Prevention of Post-Denosumab Bone Loss in Premenopausal Women with | Amgen Inc. | $450,930 | 0 |
| Denosumab in the Mutation of MAFB resulting in Multicentric Carpotarsal osteolysis syndrome (MCTO) | Amgen Inc. | $260,017 | 0 |
| Romosozumab for Premenopausal Idiopathic Osteoporosis | Amgen Inc. | $225,821 | 0 |
| GENOME-WIDE ASSOCIATION STUDY OF OSTEOCLASTIC INHIBITION BY ANTIRESORPTIVE AGENTS USING A MOUSE DIVERSITY PANEL | Amgen Inc. | $224,857 | 0 |
| MOA Femur Study | Amgen Inc. | $224,069 | 1 |
| Budoff: Fracture risk and fracture predictors in Type 2 Diabetes Mellitus | Amgen Inc. | $221,288 | 0 |
| Ph3 PMO Fracture Study | Amgen Inc. | $220,010 | 5 |
Top Doctors Receiving Payments for Prolia — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Rheumatology | Shreveport, LA | $151,914 | 180 |
| , MD | Geriatric Medicine | Durham, NC | $148,154 | 231 |
| , M.D | Rheumatology | Lafayette, LA | $143,110 | 162 |
| , M.D | Specialist | Fresno, CA | $139,789 | 208 |
| , MD | Endocrinology, Diabetes & Metabolism | W. Bloomfield, MI | $137,624 | 238 |
| , M.D | Endocrinology, Diabetes & Metabolism | Detroit, MI | $133,456 | 153 |
| , M.D | Rheumatology | Dover, NJ | $132,653 | 162 |
| , M.D | Endocrinology, Diabetes & Metabolism | Dallas, TX | $130,879 | 224 |
| , MD | Rheumatology | Charlotte, NC | $129,824 | 185 |
| , MD | Rheumatology | Cambridge, MD | $128,738 | 152 |
| , M.D | Internal Medicine | Chicago, IL | $128,501 | 171 |
| , M.D | Endocrinology, Diabetes & Metabolism | Toledo, OH | $128,262 | 155 |
| , MD | Specialist | Beverly Hills, CA | $124,041 | 209 |
| , M.D | Endocrinology, Diabetes & Metabolism | Memphis, TN | $123,835 | 112 |
| , M.D | Rheumatology | Birmingham, AL | $122,650 | 179 |
| , M.D | Rheumatology | Scottsdale, AZ | $111,947 | 145 |
| , M.D., PHD | Endocrinology, Diabetes & Metabolism | Owensboro, KY | $106,834 | 142 |
| , M.D | Endocrinology, Diabetes & Metabolism | Bethesda, MD | $103,596 | 156 |
| , M.D., M.B;B.S | Endocrinology, Diabetes & Metabolism | Bismarck, ND | $102,234 | 119 |
| , M.D | Specialist | Sacramento, CA | $97,597 | 134 |
| , MD | Endocrinology, Diabetes & Metabolism | Austin, TX | $96,116 | 137 |
| , M.D | Endocrinology, Diabetes & Metabolism | Jacksonville, FL | $94,581 | 129 |
| , M.D | Rheumatology | New York, NY | $92,977 | 129 |
| Radames Sierra-Zorita | Rheumatology | San Juan, PR | $91,562 | 98 |
| , MD | Sports Medicine | Greensboro, NC | $90,801 | 168 |
Ad
Manufacturing Companies
- Amgen Inc. $49.0M
Product Information
- Type Biological
- Total Payments $49.0M
- Total Doctors 60,768
- Transactions 308,610
About Prolia
Prolia is a biological associated with $49.0M in payments to 60,768 healthcare providers, recorded across 308,610 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2017 to 2024. In 2024, $600,946 was paid across 696 transactions to 527 doctors.
The most common payment nature for Prolia is "Unspecified" ($28.2M, 57.6% of total).
Prolia is associated with 20 research studies, including "Denosumab postlaunch safety database" ($11.1M).